BOSTON -- April 9, 2008 -- Researchers at the Joslin Diabetes Center have identified a gene that is responsible for the division and movement of marrow-derived, blood-forming stem cells, a finding that could have major implications for the future of bone marrow and blood cell transplantation.
Every year, some 45,000 patients undergo bone marrow or peripheral blood progenitor cell transplantation for the treatment of a variety of diseases, including leukemia, lymphoma, and immunodeficiency. Blood cell transplantation may also one day help people with diabetes better tolerate islet cell transplants without the need for prolonged use of powerful immunosuppressive drugs. In addition, transplantation of blood-forming stem cells, also called hematopoietic stem cells, may prove useful in halting the autoimmune process that causes type 1 diabetes.
The success of bone marrow and blood cell transplants depends on the ability of intravenously infused hematopoietic stem cells, which normally reside predominantly in the bone marrow, to accurately and efficiently migrate from the blood to the marrow of the transplant recipient and, once there, to repopulate their pool of mature blood cells.
In studying mice that lack the transcription factor early growth response gene (EGR-1), a team led by Amy Wagers, Ph.D., found that hematopoietic stem cells in the marrow of these animals divided about twice as often as stem cells in mice with the gene. Mice lacking EGR-1 also had higher numbers of such stem cells circulating in their blood.
The paper, published in the April issue of Cell Stem Cell, is the first to identify EGR-1 as a regulator of hematopoietic stem cell migration and proliferation. The transcription factor has already been identified as a tumor suppressor.
“The transcription factor EGR-1 is important in both of these processes,” said Wagers, Principal Investigator in the Joslin Section on Developmental and Stem Cell Biology, principal faculty member at the Harvard Stem Cell Institute and Assistant Professor of Pathology at Harvard Medical School. “This factor gives us a handle on the discovery of new pathways that regulate the movement of stem cells.”
The knowledge that EGR-1 suppression increases blood-forming stem cell production in the marrow and movement into the bloodstream suggests “a unique opportunity to target this pathway” to manipulate stem cell activity in the context of clinical bone marrow transplantation, the paper says.
“The process of cell migration is critical,” Wagers said. Migration of hematopoietic stem cells from the blood to the marrow is essential for effective transplantation, and the reverse process of migration from the marrow to the blood – an event called “mobilization” – is increasingly exploited for the collection of donor cells for transplant.
“By figuring out in future studies which genes this transcription factor is regulating we can find new ways, by targeting those genes, to enhance stem cell mobilization in people whose stem cells don’t mobilize well,” she said.
Bone marrow transplant patients are also vulnerable to infections in the period post-transplant when they may have insufficient numbers of blood cells. A mechanism to speed the recovery of normal levels of circulating blood cells, based on manipulations of EGR-1, would be beneficial in this manner as well, the paper points out.
The Wagers Lab at Joslin focuses on hematopoietic stem cells, which constantly maintain and can fully regenerate the entire blood system, as well as on skeletal muscle satellite cells, involved in skeletal muscle formation. This work is aimed particularly at defining novel mechanisms that regulate the migration, expansion, and regenerative potential of these two distinct adult stem cells.
The research was funded in part by a Burroughs Wellcome Fund career award, Smith Family New Investigator award, and an NIH/NIDDK training grant.
Other authors include Irene M. Min, Ph.D.; Giorgio Pietramaggio, M.D.; Francis S. Kim, all of Joslin; Emmanuelle Passegue, Ph.D., of the University of California, San Francisco; and Kristen E. Stevenson, Dana-Farber Cancer Institute.
About Joslin Diabetes Center
Joslin Diabetes Center is the world’s largest diabetes clinic, diabetes research center and provider of diabetes education. Joslin is dedicated to ensuring people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure for the disease. Founded in 1898 by Elliott P. Joslin, M.D., Joslin is an independent nonprofit institution affiliated with Harvard Medical School. For more information on Joslin, call 1-800-JOSLIN-1 or visit www.joslin.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.